Lung Adenocarcinoma Expressing an EML4‐ALK Fusion Transcript With Premature Stop Codons and Response to Alectinib: A Case Report
ABSTRACT ALK fusions are well‐established oncogenic drivers in lung cancer, typically resulting in ALK activation through dimerization mediated by partner proteins. However, alternative mechanisms of ALK activation have also been reported. We herein report an 80‐year‐old man with metastatic lung ade...
Saved in:
| Main Authors: | Mami Ozaki, Hiroaki Ikushima, Masaki Suzuki, Akira Yokoyama, Kensuke Fukuda, Kousuke Watanabe, Aya Shinozaki‐Ushiku, Motohiro Kato, Tetsuo Ushiku, Hiroyuki Aburatani, Katsutoshi Oda, Hidenori Kage |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.70146 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient
by: Kaili Huang, et al.
Published: (2025-04-01) -
Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review
by: Huang Chen, et al.
Published: (2024-12-01) -
A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review
by: Zhongzhao Wang, et al.
Published: (2024-11-01) -
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01) -
Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
by: Athanasios R Paliouras, et al.
Published: (2020-06-01)